Skip to content

Study on the pathogenesis of glaucoma secondary to exfoliation syndrome

Study on the pathogenesis of glaucoma secondary to exfoliation syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070264
Enrollment
Unknown
Registered
2023-04-07
Start date
2023-04-09
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

exfoliation syndrome group:No
PACG/POAG group:N/A
Aqueous humor control group:N/A
Trabecular tissue control group:N/A

Sponsors

The First People's Hospital of Aksu District, Xinjiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients were divided into XFG group, POAG group and control group of age equivalent receiving cataract surgery. The aqueous humor collection was included from the patients requiring age-related cataract surgery and divided into XFG, POAG and cataract control groups, while trabecular tissue selected patients in XFG and POAG groups, and control trabecular tissue was collected from the human corneal donor. 1. Inclusion criteria for the XFG group: (1) Exated material is detected in the anterior lens capsule or rim of at least one eye with dilated pupils; (2) At least one intraocular pressure of 22mmHg; (3) Glaucomatous optic neuropathy: C / D 0.7 or asymmetric cup and discs with > 0.2 or thinner retinal nerve fibers in at least one eye; (4) Visual field defect caused by glaucoma. 2. Inclusion criteria for the non-XFG POAG group: (1) No anterior lens capsule or peeling material at the margin of the pupil; (2) At least one intraocular pressure was 22mmHg; (3) The oscope or UBM examination showed normal opening of the horn; (4) Glaucomatous optic neuropathy: C / D 0.7 or asymmetric cup-disc ratio > 0.2 or thinner retinal nerve fibers in at least one eye; (5) Visual field defects caused by glaucoma; (6) Other pathogenic factors that could cause elevated IOP were excluded. 3. Inclusion criteria for the normal cataract control group: (1) No clinical manifestations of XFG; (2) No ocular lesions, except for the cataract; (3) There was no family history of glaucoma. 4. Inclusion criteria for the control group: (1) The donor had no clinical manifestations of XFG; (2) No ocular lesions, except for the cataract; (3) No family history of glaucoma; (4) Use the interim storage solution for no more than 7 days.

Exclusion criteria

Exclusion criteria: 1. Excluding patients with secondary glaucoma with other factors, including uveitis and iridocorneal endothelial syndrome; 2. Other causes of optic disc thinning (myopia, optic disc abnormalities, ischemic optic neuropathy, optic neuritis, hereditary optic neuropathy, traumatic optic neuropathy, traumatic optic neuropathy, multiple sclerosis and neurodegenerative diseases such as Alzheimer's and Parkinson's disease) were excluded; 3. Excluding other systemic or ocular diseases affecting the visual field (e. g., pituitary disease, demyelinating disease, diabetes mellitus, etc.); 4. Patients with a history of previous intraocular surgery, eye or head trauma were excluded.

Design outcomes

Primary

MeasureTime frame
RNA;Proteomics;

Countries

China

Contacts

Public ContactYing Wang

The First People's Hospital of Aksu District, Xinjiang

982491110@qq.com+86 189 9907 0367

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026